Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.47 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.37 |
| ▸ | NPY4R | P50391 | 2/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23268956 | 1.00 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL18823197 | 1.00 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL19708797 | 1.00 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL24068331 | 1.00 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL18823198 | 1.00 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL19387405 | 0.99 | FAP (0.46) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL18823482 | 0.99 | FAP (0.46) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL19750495 | 0.99 | FAP (0.46) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL20340686 | 0.98 | FAP (0.46) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL26412946 | 0.95 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| EP-4233909-A2 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2022-12-15 | — | — | US | disclosed |
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-20210252160-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | IL-2RX | 2021-08-19 | — | — | US | disclosed |
| US-10603389-B2 | Anti-cMet antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190314518-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2019-10-17 | — | — | US | disclosed |
| US-10195209-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10188660-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2017-12-07 | — | — | US | disclosed |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | CD44, SIGLEC7, SIGLEC9 | FAP 1650/4885MAP1LC3B 2719/4885SIRT2 3528/4885 |
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | FAP 575/4885MAP1LC3B 4272/4885SIRT2 4781/4885 |
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | FAP 4569/4885MAP1LC3B 729/4885SIRT2 4097/4885 |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | FAP 4569/4885MAP1LC3B 729/4885SIRT2 4097/4885 |
| US-20190314518-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | FAP 3032/4885MAP1LC3B 1941/4885SIRT2 4689/4885 |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | FAP 3032/4885MAP1LC3B 1941/4885SIRT2 4689/4885 |
| US-20210252160-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | TNFRSF9, EGFR, NGFR | FAP 1108/4885MAP1LC3B 2893/4885SIRT2 4379/4885 |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | CD2, CD2BP2, CD22 | FAP 1899/4885MAP1LC3B 3734/4885SIRT2 4882/4885 |
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | MUC1, SIGLEC7, SIGLEC9 | FAP 1009/4885MAP1LC3B 3165/4885SIRT2 3519/4885 |
| US-10188660-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | LRRC59, LRRC47, HACD3 | FAP 4569/4885MAP1LC3B 729/4885SIRT2 4097/4885 |
| US-10603389-B2 | Anti-cMet antibody drug conjugates and methods for their use | MMAB, HNMT, SHMT1 | FAP 3032/4885MAP1LC3B 1941/4885SIRT2 4689/4885 |
| US-10195209-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | LRRC59, LRRC47, HACD3 | FAP 4569/4885MAP1LC3B 729/4885SIRT2 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.